In MM, MDS and non-APL AML, the effect of ATRA drug therapy seems to be less obvious, but recent studies have found that ATRA can increase the expression of CD38 and BCMA in tumor cells, which improves the efficacy of daratumumab, CD38-CART, and BCMA-CART, which is encouraging news. This evidence concerns the gene TNFRSF17 and myelodysplastic syndrome.